​FDA approves Radius Health osteoporosis drug, but adds cancer warning

The FDA on Friday approved an osteoporosis drug made by Waltham-based Radius Health, but added a so-called "black box" warning that the treatment had increased the risk of bone cancer in rats. Radius (Nasdaq: RDUS) is hoping that abaloparatide, which will be sold under the brand name Tymlos, will eventually take on Forteo, an osteoporosis treatment sold by Eli Lilly (NYSE: LLY) that generated $1.5 billion in sales last year. Forteo has the same warning, which states that the drug increa sed the risk…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news